Assay News and Research

RSS

Effect of T cell reactivity in COVID-19 infection and vaccination

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

21 Dec 2021

QTQTN motif upstream of furin-cleavage site in SARS-CoV-2 infection and pathogenesis

A new study posted to the bioRxiv* preprint server aimed to demonstrate whether the loss of the QTQTN motif attenuates SARS-CoV-2 replication in respiratory cells in vitro and pathogenesis in hamsters.

20 Dec 2021

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

Researchers discuss the sensitivity of the SARS-CoV-2 Omicron variant towards various monoclonal antibodies.

20 Dec 2021

A test to identify antibody effectiveness against COVID-19 variants

Since the start of the COVID-19 pandemic, variants have begun to emerge. We spoke to Jacob Heggestad about his rapid test that can detect these variants.

20 Dec 2021

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

A new study expands the understanding of the impact of receiving a prophylactic monoclonal antibody infusion, as well as other variables, on the endogenous immune response to complete COVID-19 immunization.

20 Dec 2021

Efficacy of SARS-CoV2 variant-specific replicating RNA vaccines on SARS-CoV-2 variants of concern

A new study evaluates the repRNA vaccine expressing the SARS-CoV-2 spike protein for the B.1.1.7 and B.1.351 variants in mice and hamsters.

19 Dec 2021

CRISPR-based microfluidic platform detects respiratory viruses and SARS-CoV-2 variants

Researchers in the US have developed a novel multiplexed diagnostic platform based on CRISPR-based approaches and microfluidics - enabling robust and simultaneous surveillance of multiple viruses and viral variants. Currently, the paper is available on the medRxiv* preprint server pending peer review.

19 Dec 2021

Study says COVID mRNA-based vaccines best for booster vaccination

A new study looks at the adaptive immune response to COVID-19 vaccines, wherein the authors compare heterologous to homologous immunization.

19 Dec 2021

Vaccine effectiveness against COVID-19 caused by Omicron and Delta SARS-CoV-2 variants in England

Researchers performed a test-negative case-control study to determine the effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccines against the Omicron and Delta variants of SARS-CoV-2.

17 Dec 2021

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Researchers investigated the mutations reported in the Omicron variant and its likely impact on the use of therapeutic antibodies in COVID-19 treatment as well as on vaccinated individuals.

17 Dec 2021

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Researchers performed a meta-analysis of the results of four previous studies estimating fold-drop in neutralization titer against Omicron to present a combined estimate of the same.

17 Dec 2021

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

A new study reports the results of a study focused on immune evasion characteristics, specifically the ability to escape neutralization by antibodies to the earlier SARS-CoV-2 variants or to the spike antigen used in COVID-19 vaccines.

16 Dec 2021

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

The team observed that three doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine are required to mount an effective antibody response against the Omicron variant.

16 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

16 Dec 2021

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Researchers from Westmead Hospital have been investigating the effect of a third dose on neutralizing antibody titres in already vaccinated individuals.

16 Dec 2021

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

A new study assessed nAb activities against five strains of SARS-CoV-2 in paired maternal and infant cord blood samples.

15 Dec 2021

CDC researchers analyze the earliest batch of COVID-19 tests

The earliest batch of COVID-19 tests distributed by the US Centers for Disease Control and Prevention (CDC) exhibited false positive reactivity of negative controls due to flaws in assay design and contamination in one of the assay components, according to a CDC internal investigation published this week in the open-access journal PLOS ONE.

15 Dec 2021

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Researches have been investigating the possibility of using convalescent plasma to help patients recover from COVID-19.

15 Dec 2021

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Scientists from Germany have recently pointed out that the third booster dose of mRNA-based COVID-19 vaccine is highly effective in neutralizing the omicron variant of SARS-CoV-2.

15 Dec 2021

Assay News and Research

Effect of T cell reactivity in COVID-19 infection and vaccination

QTQTN motif upstream of furin-cleavage site in SARS-CoV-2 infection and pathogenesis

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

A test to identify antibody effectiveness against COVID-19 variants

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Efficacy of SARS-CoV2 variant-specific replicating RNA vaccines on SARS-CoV-2 variants of concern

CRISPR-based microfluidic platform detects respiratory viruses and SARS-CoV-2 variants

Study says COVID mRNA-based vaccines best for booster vaccination

Vaccine effectiveness against COVID-19 caused by Omicron and Delta SARS-CoV-2 variants in England

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

CDC researchers analyze the earliest batch of COVID-19 tests

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News